NK-92细胞 是从外周血单核细胞通过微粒体基因转化法衍生来的一株IL-2依赖型NK细胞株。NK-92MI细胞 是转染得到的源自NK-92细胞的IL-2非依赖的NK细胞株。所以两者的形态及生长特性大致相同 3生长形态：cell culture NK-92与NK-92MI细胞都为悬浮聚团生长，少部分细胞分散，细胞间隙会存在一些死细胞和细胞碎...
CD34 and HLA-DR. The parental IL-2 dependent cell line is available as NK-92. NK- 92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment...
悬浮细胞的生长形态一般分为单个生长和聚团生长,今天来分享两个聚团生长的细胞中,比较难养,需要注意培养技巧的细胞,分别是NK92和NK92MI cell culture 1.培养条件: NK-92 75%MEMα+0.2mM Inositol+0.1mM β-mercaptoethanol+0.02mM Folic Acid+12.5% HS+12.5% FBS+0.1mM β-Mer+200U/ml IL-2 NK-92MI 7...
悬浮细胞的生长形态一般分为单个生长和聚团生长,今天来分享两个聚团生长的细胞中,比较难养,需要注意培养技巧的细胞,分别是NK92和NK92MI cell culture 1.培养条件: NK-92 75%MEMα+0.2mM Inositol+0.1mM β-mercaptoethanol+0.02mM Folic Acid+12.5% HS+12.5% FBS+0.1mM β-Mer+200U/ml IL-2 NK-92MI 7...
cell proliferation and inducing apoptosis both in vitro and in vivo.Mechanistically,the expression of programmed cell death-ligand 1(PD-L1)in HCC cells was upregulated after co-culture with NK-92MI cells.PD-L1 expression was knocked down,thereby inhibiting the proliferation and promoting apoptosis ...
The human natural killer cell line NK92 (CRL-2407), colorectal cancer cell line HCT-116 (CCL-247), and the erythroleukemia K562 (CCL-243) were obtained from the American type culture collection (ATCC, Manassas, VA, USA). No cell line authentication was necessary. Additional information Publi...
Advances in adoptive cell immunotherapy have led to several promising options for cancer patients. Single-chain variable fragments (scFvs) were isolated from a human phage display library by panning on recombinant human leukocyte antigen (HLA)-A2-peptide
(4 × 104/ml) were treated with 25 ng/ml of IL-15,25 ng/ml of IL-21 and/or 50 nmol/L dexamethasone for 3 days and were stained with trypan blue to acquire the viable cell numbers and survival rates.Results Robo1-CAR-NK92 cells were constructed and tested 98.89% positive aft...
Multiple myeloma (MM) is a hematological malignancy caused by malignant proliferation of plasma cells in bone marrow. Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been substantially improved with the emergence of